サポート記事 · GMP / 付録 1
A technical supplement for QA, validation, and operations teams—focused on GMP expectations, Annex 1 interpretation, and practical supplier qualification checkpoints for cleanroom mops.
This article serves as a technical supplement to the primary pharmaceutical cleanroom mop supplier guide, focusing specifically on GMP and Annex 1 interpretation.
In pharmaceutical manufacturing, mop selection directly affects the robustness of the cleaning validation program. Under the revised EU GMP Annex 1, regulators place increased scrutiny on how disinfectants are applied and how residues are removed as part of routine and sporicidal cleaning.
基質が消毒活性物質に結合/中和すると、表面濃度が検証済みの対数削減目標を下回る可能性があります。
繊維の脱落により、生存不可能な粒子が増加し、EM エクスカーションのリスクと調査の負担が増大します。
モップのトレーサビリティまたは滅菌文書の欠落は、監査結果の繰り返しの原因です。
Although “mops” are not explicitly referenced in every clause, Annex 1 cleanroom cleaning requirements are inherently linked to the tools used to execute validated cleaning processes.
Annex 1 emphasizes that cleanroom design and equipment must facilitate effective cleaning. From a regulatory interpretation standpoint, this extends to tools that can access all relevant surfaces and are constructed from materials that do not harbor or generate contamination. In Grade A/B areas, contamination control principles require sterile tools introduced via a validated transfer process (e.g., double-bagged entry through an airlock). This places mop mechanical performance within the scope of cleaning process validation—not product selection alone.
Under GMP expectations, pharmaceutical cleaning tools must be manufactured from chemically inert materials. Natural fibers/foams/cellulose may degrade or interact with aggressive sporicides and high-concentration alcohols. GMP-compliant mop systems typically use knitted polyester for chemical resistance and low particle generation.
In Grade A/B cleanrooms, mops are expected to be sterile at the point of use. In Grade C/D, non-sterile but low-particulate mops may be acceptable when justified by risk assessment. For sterile applications, suppliers should provide sterilization validation—commonly gamma irradiation—demonstrating サル10⁻⁶ and batch-specific Certificates of Irradiation.
Double/triple bagging enables staged peel-and-transfer procedures; outer packaging is removed in lower grade areas and inner sterile bag opened only within Grade A/B. GMP also requires maintaining a defined “state of control”: mop heads delivered today must remain equivalent to those qualified during cleaning validation. Material/process/packaging changes should be governed under formal change control with advance notification.
サプライヤー評価に関するより広範な枠組みについては、メイン ガイドを参照してください。 製薬クリーンルームモップサプライヤーの選択.
監査に重点を置いた文書化要件については、次を参照してください。 クリーンルームモップの検証文書と COA 規格.
Supplier qualification under GMP and Annex 1 typically requires access to technical documentation and evaluation samples. You may request:
注: 正確な文書パックを作成するには、クリーンルーム グレード (A/B/C/D)、消毒剤のローテーション、無菌要件、および梱包/輸送 SOP の制約を提供します。
